US Food and Drug Administration regulatory oversight of laboratory‐developed tests: Commentary on the draft guidance

Publisher： John Wiley & Sons Inc

E-ISSN： 1934-6638|123|10|573-575

ISSN： 1934-662x

Source： CANCER CYTOPATHOLOGY, Vol.123, Iss.10, 2015-10, pp. : 573-575

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA's draft guidance on laboratory‐developed tests increases clinical and economic risk to adoption of pharmacogenetic testing

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 7, 2015-07 ,pp. : 725-727

John Wiley & Sons Inc

Access to resources Recommend Favorite

FDA oversight of laboratory‐developed tests will facilitate adoption of pharmacogenetic testing into routine clinical care

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 7, 2015-07 ,pp. : 728-730

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety assessment of niacin in the US Food and Drug Administration's mini‐sentinel system

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 27, Iss. 1, 2018-01 ,pp. : 30-37

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration

By  

CANCER, Vol. 121, Iss. 10, 2015-05 ,pp. : 1688-1693

John Wiley & Sons Inc

Access to resources Recommend Favorite

Proceedings of the Food and Drug Administration's public workshop on new red blood cell product regulatory science 2016

By  

TRANSFUSION, Vol. 58, Iss. 1, 2018-01 ,pp. : 255-266

John Wiley & Sons Inc

Access to resources Recommend Favorite